DEA’s New Telemedicine Policies: A Prescription for Change?
The DEA introduces new rules reshaping telemedicine, particularly affecting the prescribing of buprenorphine for opioid use disorder (OUD) treatment. Clinicians can now prescribe Schedule III-V controlled substances for six months…